Search hospitals > Michigan > Ann Arbor

University of Michigan, Kellogg Eye Center

Claim this profile
Ann Arbor, Michigan 48105
Global Leader in Retinitis Pigmentosa
Global Leader in Macular Retinitis
Conducts research for Age-Related Macular Degeneration
Conducts research for None
Conducts research for Retinal Dystrophy
77 reported clinical trials
8 medical researchers
Photo of University of Michigan, Kellogg Eye Center in Ann ArborPhoto of University of Michigan, Kellogg Eye Center in Ann ArborPhoto of University of Michigan, Kellogg Eye Center in Ann Arbor

Summary

University of Michigan, Kellogg Eye Center is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Retinitis Pigmentosa, Macular Retinitis, Age-Related Macular Degeneration, None, Retinal Dystrophy and other specialties. University of Michigan, Kellogg Eye Center is involved with conducting 77 clinical trials across 107 conditions. There are 8 research doctors associated with this hospital, such as Thiran Jayasundera, MD, Cagri Besirli, Shahzad Mian, MD, and Susan G Elner, MD.

Area of expertise

1Retinitis Pigmentosa
Global Leader
University of Michigan, Kellogg Eye Center has run 21 trials for Retinitis Pigmentosa. Some of their research focus areas include:
PRPF31 positive
USH2A exon 13 mutations positive
USH2A positive
2Macular Retinitis
Global Leader
University of Michigan, Kellogg Eye Center has run 19 trials for Macular Retinitis. Some of their research focus areas include:
PRPF31 positive
USH2A exon 13 mutations positive
USH2A positive

Top PIs

Clinical Trials running at University of Michigan, Kellogg Eye Center

Age-Related Macular Degeneration
Retinal Disease
Retinitis Pigmentosa
Retinal Dystrophy
Stargardt Disease
Macular Retinitis
None
Retinal Degeneration
Eye Diseases
Glaucoma
Image of trial facility.

Stem Cell Therapy

for Dry Age-Related Macular Degeneration

This trial is testing a new treatment where cells from donor eyes are transplanted into patients with dry AMD to see if it is safe and can help improve their vision. Stem cell transplantation may improve visual acuity in patients with dry age-related macular degeneration.
Recruiting1 award Phase 1 & 2
Image of trial facility.

ACDN-01

for Stargardt Disease

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Recruiting1 award Phase 1 & 23 criteria
Image of trial facility.

Elamipretide

for Age-Related Macular Degeneration

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
Recruiting1 award Phase 32 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Michigan, Kellogg Eye Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security